Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLCO Bausch + Lomb	$14.25 +2.0%	$12.64	$10.45 ▼ $21.69	$4.94B	0.62	775,715 shs	1.76 million shs
IRTC iRhythm Technologies	$134.18 +1.4%	$142.46	$55.92 ▼ $157.13	$4.22B	1.41	414,071 shs	184,629 shs
LQDA Liquidia Technologies	$19.60 +4.4%	$14.83	$8.26 ▼ $19.76	$1.60B	-0.01	2.18 million shs	3.77 million shs
SLNO Soleno Therapeutics	$86.47 -1.8%	$80.79	$41.50 ▼ $90.32	$4.44B	-2.63	1.46 million shs	790,648 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLCO Bausch + Lomb	-1.41%	-0.90%	+16.44%	+2.44%	-13.08%
IRTC iRhythm Technologies	-1.74%	-2.56%	-13.90%	+24.81%	+35.88%
LQDA Liquidia Technologies	+5.75%	+28.56%	+36.21%	+32.93%	+65.52%
SLNO Soleno Therapeutics	+0.66%	+0.45%	+4.59%	+20.16%	+82.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLCO Bausch + Lomb	2.0649 of 5 stars	2.1	2.0	0.0	1.9	1.7	2.5
IRTC iRhythm Technologies	1.0411 of 5 stars	2.5	1.0	0.0	2.2	0.8	0.6
LQDA Liquidia Technologies	3.3143 of 5 stars	4.5	0.0	0.0	2.1	4.2	0.6
SLNO Soleno Therapeutics	4.2984 of 5 stars	3.5	1.0	4.6	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLCO Bausch + Lomb	2.17	Hold	$15.45	8.45% Upside
IRTC iRhythm Technologies	2.90	Moderate Buy	$137.30	2.33% Upside
LQDA Liquidia Technologies	3.00	Buy	$26.89	37.19% Upside
SLNO Soleno Therapeutics	3.09	Buy	$108.70	25.71% Upside

Current Analyst Ratings Breakdown

Latest LQDA, BLCO, SLNO, and IRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$160.00 ➝ $147.00
7/11/2025	SLNO Soleno Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $121.00
7/9/2025	BLCO Bausch + Lomb	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $15.00
7/8/2025	BLCO Bausch + Lomb	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$15.50 ➝ $16.00
6/23/2025	SLNO Soleno Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	SLNO Soleno Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$110.00
6/12/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$23.00 ➝ $25.00
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
6/11/2025	LQDA Liquidia Technologies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $23.00
6/9/2025	BLCO Bausch + Lomb	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$19.00 ➝ $16.00
6/2/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLCO Bausch + Lomb	$4.79B	1.05	$1.91 per share	7.46	$18.57 per share	0.77
IRTC iRhythm Technologies	$591.84M	7.24	N/A	N/A	$2.90 per share	46.27
LQDA Liquidia Technologies	$14M	119.69	N/A	N/A	$0.91 per share	21.54
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLCO Bausch + Lomb	-$317M	-$1.03	N/A	14.84	1.57	-7.50%	2.62%	1.28%	7/30/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$3.14	N/A	N/A	N/A	-15.90%	-101.04%	-9.55%	7/31/2025 (Estimated)
LQDA Liquidia Technologies	-$130.39M	-$1.58	N/A	N/A	N/A	-903.80%	-177.91%	-60.15%	8/6/2025 (Estimated)
SLNO Soleno Therapeutics	-$175.85M	-$4.62	N/A	N/A	N/A	N/A	-77.52%	-63.44%	8/6/2025 (Estimated)

Latest LQDA, BLCO, SLNO, and IRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	LQDA Liquidia Technologies	-$0.43	N/A	N/A	N/A	$3.90 million	N/A
8/6/2025	Q2 2025	SLNO Soleno Therapeutics	-$0.85	N/A	N/A	N/A	$3.91 million	N/A
7/31/2025	Q2 2025	IRTC iRhythm Technologies	-$0.53	N/A	N/A	N/A	$173.94 million	N/A
7/30/2025	Q2 2025	BLCO Bausch + Lomb	$0.07	N/A	N/A	N/A	$1.25 billion	N/A
5/8/2025	Q1 2025	LQDA Liquidia Technologies	-$0.42	-$0.45	-$0.03	-$0.45	$3.23 million	$3.12 million
5/7/2025	Q1 2025	SLNO Soleno Therapeutics	-$1.14	-$0.95	+$0.19	-$0.95	N/A	N/A
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million
4/30/2025	Q1 2025	BLCO Bausch + Lomb	$0.03	-$0.07	-$0.10	-$0.60	$1.15 billion	$1.15 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLCO Bausch + Lomb	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLCO Bausch + Lomb	0.74	1.56	0.96
IRTC iRhythm Technologies	7.47	5.71	5.58
LQDA Liquidia Technologies	2.08	2.93	2.91
SLNO Soleno Therapeutics	0.21	19.64	19.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLCO Bausch + Lomb	11.07%
IRTC iRhythm Technologies	N/A
LQDA Liquidia Technologies	64.54%
SLNO Soleno Therapeutics	97.42%

Insider Ownership

Company	Insider Ownership
BLCO Bausch + Lomb	0.76%
IRTC iRhythm Technologies	1.10%
LQDA Liquidia Technologies	26.50%
SLNO Soleno Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLCO Bausch + Lomb	13,500	353.80 million	351.12 million	Optionable
IRTC iRhythm Technologies	2,000	31.92 million	31.57 million	Optionable
LQDA Liquidia Technologies	50	85.49 million	62.83 million	Optionable
SLNO Soleno Therapeutics	30	50.39 million	47.17 million	Optionable

LQDA, BLCO, SLNO, and IRTC Headlines

Recent News About These Companies

Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?

July 25 at 1:00 PM | zacks.com

Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength

July 23 at 2:09 PM | msn.com

Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?

July 23 at 10:56 AM | zacks.com

40,425 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Purchased by Y Intercept Hong Kong Ltd

July 23 at 5:49 AM | marketbeat.com

Readystate Asset Management LP Buys 49,422 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

July 22 at 1:14 PM | marketbeat.com

Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations

July 21, 2025 | msn.com

Brokers Set Expectations for SLNO FY2025 Earnings

July 20, 2025 | americanbankingnews.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Atle Fund Management AB

July 19, 2025 | marketbeat.com

11 Best Performing Mid Cap Stocks So Far In 2025

July 18, 2025 | insidermonkey.com

FY2025 EPS Estimates for SLNO Raised by Cantor Fitzgerald

July 18, 2025 | marketbeat.com

Bank of New York Mellon Corp Buys 234,649 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

July 18, 2025 | marketbeat.com

Soleno Therapeutics: Fairly Valued Despite M&A Expectations

July 16, 2025 | seekingalpha.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by TimesSquare Capital Management LLC

July 15, 2025 | marketbeat.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is Emerald Advisers LLC's 8th Largest Position

July 13, 2025 | marketbeat.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is Emerald Mutual Fund Advisers Trust's 7th Largest Position

July 12, 2025 | marketbeat.com

Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing

July 11, 2025 | msn.com

Soleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, Robert W. Baird Analyst Says

July 11, 2025 | marketbeat.com

Soleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume - Time to Buy?

July 10, 2025 | marketbeat.com

Soleno Therapeutics stock dips on proposed $200M offering

July 10, 2025 | msn.com

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

July 10, 2025 | globenewswire.com

Soleno Therapeutics, Inc. Announces $200 Million Public Offering to Fund VYKAT XR Commercialization and R&D Activities

July 10, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, BLCO, SLNO, and IRTC Company Descriptions

Bausch + Lomb NYSE:BLCO

$14.25 +0.28 (+2.01%)

Closing price 03:59 PM Eastern

Extended Trading

$14.51 +0.26 (+1.82%)

As of 06:12 PM Eastern

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

iRhythm Technologies NASDAQ:IRTC

$134.18 +1.89 (+1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$134.20 +0.01 (+0.01%)

As of 04:20 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Liquidia Technologies NASDAQ:LQDA

$19.60 +0.83 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$19.61 +0.01 (+0.08%)

As of 07:53 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Soleno Therapeutics NASDAQ:SLNO

$86.47 -1.56 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$86.48 +0.00 (+0.01%)

As of 07:51 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time